Zenas BioPharma shares rise 10.85% intraday as company to present autoimmune disease therapy updates at Guggenheim 2026 Biotech Summit.
ByAinvest
Wednesday, Feb 4, 2026 10:45 am ET1min read
ZBIO--
Zenas BioPharma surged 10.85% intraday, announcing that its management will present at the Guggenheim Emerging Outlook: 2026 Biotech Summit on February 11, 2026. The presentation will cover R&D progress in autoimmune disease therapies and will be webcast via the company's website. The firm is a clinical-stage global biopharma company focused on developing transformative therapies for autoimmune diseases, currently advancing two late-stage candidates: obexelimab and orelabrutinib.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet